ArticleInternational journal of molecular sciences2023
Characterization and Comparative Genomic Analysis of Three Virulent
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Efficacy of a novel bacteriophage in controlling Escherichia coli associated with swine farm environments and its potential for biofilm disruption.Scientific reports · 2026Article
- Physicochemical, genomic, and phenotypic characterization ofMicrobiology spectrum · 2025Article
- Bacteriophages Improve the Effectiveness of Rhamnolipids in Combating the Biofilm ofMolecules (Basel, Switzerland) · 2025Article
- Genomic and proteomic characterization of four novel Schitoviridae family phages targeting uropathogenic Escherichia coli strain.Virology journal · 2025Article
- Molecular characterization and safety properties of multi drug-resistant Escherichia coli O157:H7 bacteriophages.BMC microbiology · 2024Article
- Characterization of bacteriophages infecting multidrug-resistant uropathogenic Escherichia coli strains.Archives of virology · 2024Article
- Exploring the Bacteriophage Frontier: A Bibliometric Analysis of Clinical Trials Between 1965 and 2024.Cureus · 2024Review
- Safety Properties ofFoods (Basel, Switzerland) · 2023Review
- NovelPHAGE (New Rochelle, N.Y.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The emerging global crisis of antibiotic resistance demands new alternative antibacterial solutions. Although bacteriophages have been used to combat bacterial infections for over a century, a dramatic boost in phage studies has recently been observed. In the development of modern phage applications, a scientific rationale is strongly required and newly isolated phages need to be examined in detail. In this study, we present the full characterization of bacteriophages BF9, BF15, and BF17, with lytic activity against extended-spectrum β-lactamases (ESBLs)- and AmpC β-lactamases (AmpC)-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.